Intranodal immunization with a dendritic cell tumor vaccine is more effective than subcutaneous or intravenous routes

Abstract

Introduction: In murine tumor models, tumor antigen-pulsed dendritic cells (DCs) administered subcutaneously (SC) can generate anti-tumor immune responses. However, only a small fraction of SC injected DCs migrate to regional lymph nodes and activate T-lymphocytes. Therefore, we compared the potency of 3 different routes of administration of a murine tumor lysate-pulsed DC vaccine: SC, intravenous (IV) and directly into a lymph node (LN).